Marshall Edwards, Inc. (MSHL) is Taking a New Approach to Oncology
Marshall Edwards, a subsidiary of the Australian pharmaceutical company, Novogen Limited, was formed with the specific intent of increasing the focus on an important new oncological discovery known as multiple signal transduction regulators (MSTRs). Novogen scientists discovered these regulators, and brought Marshall Edwards onboard to develop the products commercially. The main MSTR, called Phenoxodiol, is currently undergoing Phase III clinical testing in the US, Europe, and Australia. The drug is being developed for the treatment of both early and late-stage prostate and cervical cancer, as well as ovarian cancers that have proven to be resistant to chemotherapy. Phenoxodiol promotes the…